1 Background
1.1 Emphasis on consumer
safety
According to the Council
Directive "a cosmetic product
put on the market within the
Community must not cause damage
to human health when applied
under normal or reasonably
foreseeable conditions of use"
(76/768/EEC). In order to
achieve this goal of product
safety, toxicological data on
cosmetic ingredients are needed
as outlined in the SCCNFP Notes
of Guidance for Testing of
Cosmetic Ingredients for their
Safety Evaluation 2nd Rev.
(XXIV/1878/97). Among the data
mentioned, also «human data»
are cited. However, the
document does not specify these
in detail. Regarding skin
irritation, the SCCNFP
considers that at present human
testing of cosmetic ingredients
or mixtures of ingredients
should not be preferred to
animal testing.
1.2 Animal tests for
assessment of safety to be
replaced by alternative
methods
In the past, most of the
toxicological data mentioned
above have been generated by
testing on animals. However,
according to Council Directive
76/768/EEC, the marketing of
cosmetic products containing
ingredients or combinations of
ingredients tested on animals
after 30 June 2000 in order to
meet the requirements of this
Directive shall be prohibited.
The Commission's general policy
regarding research on animals
supports the development of
alternative methods to reduce
or replace animal testing when
possible.
1.3 Testing of cosmetic
ingredients in humans
In this context, the
scientific and ethical
considerations for testing
cosmetic ingredients or
mixtures of ingredients in
human subjects need to be
defined more clearly. The skin
irritancy reaction in humans is
not an absolute measure and
must be related to appropriate
controls defining the range of
response.
The SCCNFP stresses
three points:
1. Since tests in
animals or validated
alternative methods may be
limited regarding their
predictive value for exposure
of a human population,
confirmatory safety tests in
humans may be necessary
scientifically and ethically,
provided that the toxicological
profile of an ingredient or a
mixture of ingredients based on
animal or alternative methods
is available and that a high
degree of safety is to be
expected.
2. Confirmatory tests of
ingredients or mixtures of
ingredients in humans must be
limited to situations where no
irreversible damaging effects
are to be expected for the
volunteers and where the study
goal is reasonably achievable
with a study population of
limited size.
3. The recruitment of
human volunteers should be in
line with the "World Medical
Doctors Association Declaration
of Helsinki" and "the Good
Clinical Practice for trials on
Medicinal Products in the
European Community."
2 Procedure of irritancy
assessment
The following text
outlines the steps of an
assessment of the irritancy of
an ingredient or mixture of
ingredients. While this text
focuses on irritancy, it is
understood that other aspects
of toxicity have to be
considered in parallel before
performing tests in humans.
2.1 Initial
considerations
Available chemical and
physico-chemical data and
structure-activity
relationships making use of
computer programs and databases
for the prediction of skin
irritation potential should be
used.
2.2 Evaluation of
irritation
Ingredients or mixtures
of ingredients should be tested
on animals and humans only at
non-corrosive concentrations.
This decision may be based on
pH and acid/alkaline reserve
measurements and on in vitro
tests for skin corrosivity. At
the present, in vitro methods
for the assessment of irritancy
have not yet been validated.
2.3 Confirmation by human
volunteer testing
On the basis of a low
irritation potential as proven
by animal or future validated
in vitro methods, the skin
tolerability of an ingredient
or a mixture of ingredient can
be confirmed by testing in
human volunteers. A number of
test protocols are available
such as open and closed patch
tests, single and
repeated-exposure tests. They
should be chosen on the basis
of the relevant use pattern of
the ingredient or mixture of
ingredients (1).
- In the open test, the
tested ingredient or mixture of
ingredients is applied on the
skin without occlusion for time
periods between 15 min and 24
h.
- In closed patch tests,
diluted or undiluted products
are applied under occlusive
chambers over 24 or 48 hours.
- Cumulative or
repetitive closed patch tests
involve applications on the
same test site between 1 and 7
times per week over a period of
1 to 5 weeks. These repetitive
tests allow the assessment of
cumulative irritation that is
missed by single application
tests.
- Controlled use or
repeated open application tests
(ROAT) imply the repeated
application of an ingredient or
a mixture of ingredients
closely modelled to the
use-situation.
While these tests
historically have been assessed
by clinical methods,
non-invasive bioengineering
technology such as measurement
of transepidermal water loss or
of blood flow may provide
higher sensitivity and
objectivity of these tests and
thereby reduce the exposure and
risk to volunteers.
However, neither the
above confirmatory tests nor
the use of bioengineering
methods have been validated
according to modern scientific
criteria. The SCCNFP recommends
the Commission to support
further research in this area.
2.4 Consumer market
surveillance
The evaluation of
irritation of an ingredient or
mixture of ingredients is not
finished with the introduction
of respective cosmetic products
on the market, but it should
continue by making use of data
generated by consumer market
surveillance and other sources.
3 Ethical considerations
Confirmatory skin
tolerance tests of cosmetic
ingredients in humans are
subject to ethical concerns. In
order to take account of these
concerns, to minimise the risk
to volunteers and to safeguard
their rights, test protocols
should be submitted to an
acknowledged ethical committee
and be in compliance with the
followings :
- World Medical Doctors
Association Declaration of
Helsinki in its current
revision (2).
Human testing is to be
conducted and monitored under
the direction of relevantly
trained personnel to ensure the
health and well being of
volunteer subjects involved in
the testing. The health and
welfare of the subject has
first priority and must be
highly protected. Importantly,
the human testing that is
conducted for chemicals and
consumer products is associated
with minimal risk as it is
conducted:
i) to supplement
non-clinical information,
ii) to confirm that
exposure will not cause
significant harm, and/or,
iii) in a controlled
fashion that minimises subject
risk (4).
- National regulations
regarding human studies
- Good Clinical Practice
for Trials on Medicinal
Products in the European
Community (3).
The investigator(s) in
skin tolerability tests of
cosmetic ingredients should
fulfil the qualifications as
mentioned in the CPMP Working
Party on Efficacy of Medicinal
Products Note for Guidance on
Good Clinical Practice (3).
4 References
(1) Patrick E, Maibach
HI: Predictive assays: Animal
and man, and in vitro and in
vivo. In: Rycroft R.J.G., Menne
T., Frosch P.J., (1995)
Textbook of Contact Dermatitis.
Springer Heidelberg New York.
(2) World Medical
Doctors Association Declaration
of Helsinki, (1997) JAMA 227:
925-926
(3) CPMP Working Party
on Efficacy of Medicinal
Products Note for Guidance:
Good Clinical Practice for
Trials on Medicinal Products in
the European Community (1990)
CB-55-89-706-EN-C.
(4) Organisation for
Economic Co-operation and
Development: Development of
OECD Test Guidelines for Use in
Tests with Human Volunteers.
27th Joint Meeting of the
Chemicals Group and Management
Committee, 11th-13th February
1998 (ENV/MC/CHEM/RD (98))